NASDAQ · ANIP
ANI Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$72.58▲ 0.55% ($0.40)at close
After hours$72.40▼ 0.25%7:53 PM ET
Market cap
$1.65B
P/E
15.03
EPS (TTM)
$4.83
Next earnings
Nov 6, 2026
Valuation
Revenue & margin DCF
Verdict: cheap. Price below all scenarios.
The price holds with revenue shrinking 10.9% a year for 10 years. Our scenarios assume 13.7–23.9%.
That's below its past 4-year pace of 42.2%.
Value per share
Base case
$683.45
Price used $72.58 is 89% below this
USD · TTM ending Jun 30, 2026 · Price Oct 5, 8:00 PM UTC
This estimate is at least 3× the price used. Review the growth, margin and investment assumptions behind the gap.
Revenue each value needs
Revenue today $978M. The price needs $309M by 2036. Base case: $5.6B. At its recent pace: $33B. Bear to Bull: $3.5B to $8.3B.
Revenue today $978M. The price needs $309M by 2036. Base case: $5.6B. At its recent pace: $33B. Bear to Bull: $3.5B to $8.3B.
Revenue in 2036
today $978M
−$5.3Bless than the Base case
Value per share · Base case
$683.45
Price $72.58
89% below this
- 10-yr revenue CAGR
- 19.1%
- Ending operating margin
- 18.3%
- Discount rate
- 7.3%
This estimate is at least 3× the price used. Review the growth, margin and investment assumptions behind the gap.
USD · TTM ending Jun 30, 2026 · Price Oct 5, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 21.16% over the last year. Revenue grew 30.9% over the trailing twelve months. Operating margin moved from 2.03% to 15.35%. Free cash flow grew 51.72% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price, and the shares now sit around the 5th percentile of their historical P/FCF range. That looks more like a rerating of the multiple than a collapse in the business.
What would invalidate this read
This read changes if operating margin (currently 15.35%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Return analysis
Company profile
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.
Market multiples
Stock splits
Every 6 shares became 1
Every 6 shares became 1
Every 10 shares became 1
Profitability & growth
Analyst consensus
6
Buy
4
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 6, 2026
Q3 FY26 · EPS est $2.17 · Revenue est $280.84M
View
Institutional Sentiment
ANI Pharmaceuticals, Inc. · ANIP
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.